³í¹®) Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients with Chronic Hepatitis B ¼¿ï´ëº´¿ø ³»°ú ÀÌÁ¤ÈÆ ±³¼ö(»çÁø ñ§) ÆÀ(º¸¶ó¸Åº´¿ø ÀåÈñÁØ ±³¼ö(ñé), ºÎ»ê¹éº´¿ø À±ÁØ½Ä ±³¼ö éÓ)